ALT Altimmune Pharma: Quarterly EPS earnings growth

Official company branding of Altimmune, Inc. (ALT)

Altimmune, Inc. (ALT) relies on external contractors for testing and manufacturing, creating a strong operational dependency. Quarterly earnings per share (EPS) growth illustrates the profitability trend, where the current value of the indicator is 54.40. The launch of pemvidutide for obesity treatment remains the priority. The market expects management to secure strategic deals to ensure the successful commercialization of the product.

Altimmune (ALT) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/12/2026

Summary analytical data breakdowns for Altimmune Pharma (ALT)

- share price and expert price forecast:
Stock Price Altimmune|ALT - Analyst Consensus Forecast
- company stock capitalization data:
Market Capitalization Altimmune Corp|ALT - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Altimmune|ALT - Total Stockholders' Equity|Market Value to Book Value Ratio altimmune.com|ALT - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Capital Altimmune, Inc.|ALT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Altimmune, Inc.|ALT - Company Total Debt Obligations|Debt to Book Capitalization Ratio Altimmune Corp|ALT - Company Long-Term Liabilities|Company Short-Term Debts Altimmune|Quick Liquidity altimmune.com
- earnings and market multiples details:
ALT - Company Net Income|Future Profit Altimmune, Inc.|ALT - Market Price to Net Income Ratio|Forward P/E Multiple Altimmune Corp|ALT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp|ALT - Operating profit before deduction of amortization|Earnings per share for the last twelve months Altimmune|ALT - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months altimmune.com|ALT - Earnings growth in current year|Net earnings per share growth forecast for next year Altimmune, Inc.
Analysis of all company metrics:Altimmune, Inc.
Flagship merchandise of Altimmune, Inc.

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This trend allows investors to assess the actual scaling speed of the business and avoid overpaying for the asset. Analyzing the quarterly EPS growth trend reveals the impact of capital expenditures on profitability. For Altimmune, Inc. (ALT), this is critical when hiring market access and clinical trial experts. Retaining the scientific core during aggressive management expansion directly determines the future profit trajectory.

Main competitors

ASND: Quarterly EPS earnings growth|Madrigal Pharmaceuticals Inc (MDGL) - Quarterly EPS earnings growth|CORT (Corcept) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months RYTM|Year-over-year earnings per share growth for the last twelve months Akero Therapeutics (AKRO)|MTSR - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months MoonLake MLTX|Crinetics Pharmaceuticals, Inc. - Year-over-year earnings per share growth for the last twelve months|NewAmsterdam Pharma N.V. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Soleno Therapeutics Corp SLNO|Amicus Therapeutics (FOLD) - Year-over-year earnings per share growth for the last twelve months|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Pharmaceuticals, Inc.|Year-over-year net earnings per share growth for the last 12 months Structure Therapeutics Inc (GPCR)|Quarterly EPS earnings growth MDXG|Quarterly EPS earnings growth Rezolute Bio (RZLT)|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals LXRX|mbxbio.com - Year-over-year earnings per share growth for the last twelve months|AARD: Year-over-year net earnings per share growth for the last 12 months|Sagimet Biosciences, Inc. - Year-over-year earnings per share growth rate for the last twelve months|BIOA: Quarterly EPS earnings growth|BMEA - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics Inc|Year-over-year net earnings per share growth for the last 12 months fractyl.com (GUTS)|Year-over-year earnings per share growth for the last twelve months vTv Therapeutics Inc. (VTVT)|Year-over-year net earnings per share growth for the last 12 months agapeatpgroup.com ATPC|Pluri - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Synlogic Inc. SYBX|LPCN - Year-over-year earnings per share growth for the last twelve months|MTNB (Matinas BioPharma) - Year-over-year earnings per share growth for the last 12 months|SPRB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Galecto Inc (GLTO)|Year-over-year net earnings per share growth for the last 12 months CTCX|LUMO: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share change for the last twelve months radiuspharm.com